BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35813008)

  • 1. LI-RADS Classification and Outcomes of Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.
    Tachibana Y; Takaji R; Maruno M; Honda K; Endo M; Murakami K; Asayama Y
    Cancer Diagn Progn; 2022; 2(4):471-481. PubMed ID: 35813008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
    Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
    Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules.
    Choi SH; Byun JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Radiology; 2018 May; 287(2):515-524. PubMed ID: 29457964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced ultrasound liver imaging reporting and data system v2017: patient outcomes after treatment for early-stage hepatocellular carcinoma nodules with category 3-5 and category M.
    Hu YX; Yan CJ; Yun M; Zheng W; Zou XB; Zhang YF; Mao RS; Li LL; Zhou JH
    Br J Radiol; 2023 Jul; 96(1147):20220492. PubMed ID: 37066834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
    Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
    AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis.
    Romano P; Busti M; Billato I; D'Amico F; Marchegiani G; Pelizzaro F; Vitale A; Cillo U
    BJS Open; 2024 Jan; 8(1):. PubMed ID: 38323881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study.
    Yan J; Man Z; Lu Q; Ma K
    Cancer Manag Res; 2020; 12():2613-2621. PubMed ID: 32368139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.
    Ishikawa K; Chiba T; Ooka Y; Suzuki E; Ogasawara S; Maeda T; Yokoyama M; Inoue M; Wakamatsu T; Kusakabe Y; Saito T; Tawada A; Arai M; Kanda T; Maruyama H; Imazeki F; Kato N
    Oncotarget; 2018 Apr; 9(30):21560-21568. PubMed ID: 29765560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver resection, radiofrequency ablation, and radiofrequency ablation combined with transcatheter arterial chemoembolization for very-early- and early-stage hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis for comparison of efficacy.
    Zhang Y; Qin Y; Dong P; Ning H; Wang G
    Front Oncol; 2022; 12():991944. PubMed ID: 36387091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.
    Zhang Y; Wang J; Li H; Zheng T; Jiang H; Li M; Song B
    Ann Transl Med; 2020 Mar; 8(6):388. PubMed ID: 32355832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
    Li L; Xin Y; Zhang X; Chen Y; Yang Y; Zhou X; Ye F
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101878. PubMed ID: 35151909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
    Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
    Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.
    Jiang C; Cheng G; Liao M; Huang J
    World J Surg Oncol; 2021 Mar; 19(1):81. PubMed ID: 33741001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Liver Resection and Transarterial Chemoembolization in Patients with Multinodular BCLC-A Hepatocellular Carcinoma.
    Yang J; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Moon DB; Jung DH; Choi J
    J Liver Cancer; 2024 Apr; ():. PubMed ID: 38566326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
    Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
    Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.